BACKGROUND: Although the incidence of atrial fibrillation (AF) progressively increases with age, the vast majority of AF ablation is done in middle-aged patients. We evaluated the feasibility and safety of catheter ablation in patients older than 65 years of age with paroxysmal and persistent AF. METHODS: Out of a total of 230 consecutive AF ablation procedures, 45 patients were older than 65 years of age and underwent 53 procedures. The ablation strategy consisted of wide-area circumferential lines around both ipsilateral pulmonary veins using a three-dimensional mapping system. RESULTS: The mean age was 69 ± 3.5 years (35 males). The mean duration for AF was 8.7 ± 6.5 years. Thirty-nine had paroxysmal and six persistent AF despite use of 1.38 ± 0.77 antiarrhythmic drugs. All patients had a structurally normal heart. Eleven had systemic hypertension. Mean procedure time was 187 ± 33 min. Acute procedural success rate with abolition of all pulmonary vein potentials was achieved in all patients. Pericardial tamponade requiring percutaneous drainage occurred in one (1.9%) patient. There were no cardioembolic events. Among the 43 patients whose clinical outcome was assessed at 6 months, 34 (79%) had a significant reduction (>90%) of the total symptomatic AF burden, compared to pre-ablation, with a complete lack of symptomatic AF in 32 (74%) patients. The success rate was higher for patients with paroxysmal versus persistent AF (81 vs. 67%). Six patients (11%) underwent repeat procedures. CONCLUSIONS: Catheter ablation is a safe and effective treatment for patients over the age of 65 years with symptomatic, drug-refractory AF. Therefore, patients should not be excluded from undergoing AF catheter ablation on the basis of age alone.
BACKGROUND: Although the incidence of atrial fibrillation (AF) progressively increases with age, the vast majority of AF ablation is done in middle-aged patients. We evaluated the feasibility and safety of catheter ablation in patients older than 65 years of age with paroxysmal and persistent AF. METHODS: Out of a total of 230 consecutive AF ablation procedures, 45 patients were older than 65 years of age and underwent 53 procedures. The ablation strategy consisted of wide-area circumferential lines around both ipsilateral pulmonary veins using a three-dimensional mapping system. RESULTS: The mean age was 69 ± 3.5 years (35 males). The mean duration for AF was 8.7 ± 6.5 years. Thirty-nine had paroxysmal and six persistent AF despite use of 1.38 ± 0.77 antiarrhythmic drugs. All patients had a structurally normal heart. Eleven had systemic hypertension. Mean procedure time was 187 ± 33 min. Acute procedural success rate with abolition of all pulmonary vein potentials was achieved in all patients. Pericardial tamponade requiring percutaneous drainage occurred in one (1.9%) patient. There were no cardioembolic events. Among the 43 patients whose clinical outcome was assessed at 6 months, 34 (79%) had a significant reduction (>90%) of the total symptomatic AF burden, compared to pre-ablation, with a complete lack of symptomatic AF in 32 (74%) patients. The success rate was higher for patients with paroxysmal versus persistent AF (81 vs. 67%). Six patients (11%) underwent repeat procedures. CONCLUSIONS: Catheter ablation is a safe and effective treatment for patients over the age of 65 years with symptomatic, drug-refractory AF. Therefore, patients should not be excluded from undergoing AF catheter ablation on the basis of age alone.
Authors: Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin Journal: Heart Rhythm Date: 2007-04-30 Impact factor: 6.343
Authors: Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: T Jared Bunch; J Peter Weiss; Brian G Crandall; Heidi T May; Tami L Bair; Jeffrey S Osborn; Jeffrey L Anderson; Donald L Lappe; J Brent Muhlestein; Jennifer Nelson; John D Day Journal: Pacing Clin Electrophysiol Date: 2009-11-02 Impact factor: 1.976
Authors: Hakan Oral; Aman Chugh; Eric Good; Sundar Sankaran; Stephen S Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Thomas Crawford; Sujoya Dey; Alan Wimmer; Kristina Lemola; Krit Jongnarangsin; Frank Bogun; Frank Pelosi; Fred Morady Journal: Circulation Date: 2006-04-10 Impact factor: 29.690
Authors: M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty Journal: N Engl J Med Date: 1998-09-03 Impact factor: 91.245
Authors: S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245
Authors: Steven C Hao; Tina D Hunter; Candace Gunnarsson; Jamie L March; Sarah A White; Joseph A Ladapo; Matthew R Reynolds Journal: J Interv Card Electrophysiol Date: 2012-06-20 Impact factor: 1.900
Authors: Laurent M Haegeli; Thomas Wolber; Ercüment Ercin; Lukas Altwegg; Nazmi Krasniqi; Paul G Novak; Laurence D Sterns; Corinna B Brunckhorst; Thomas F Lüscher; Richard A Leather; Firat Duru Journal: Cardiol Res Pract Date: 2010-12-13 Impact factor: 1.866
Authors: Henrica N A M van Breugel; Orlando Parise; Fred H M Nieman; Ryan E Accord; Fabiana Lucà; Pieter Lozekoot; Narendra Kumar; Ghislaine A P G van Mastrigt; Jan F M A Nijs; Ries Vrakking; Jos G Maessen; Mark La Meir; Sandro Gelsomino Journal: J Cardiothorac Surg Date: 2016-05-03 Impact factor: 1.637